(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DAR No 1. Indacaterol (Onbrez breezhaler®) Maintenance bronchodilator therapy in patients with COPD

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

Uncertainty regarding safety

  • Indacaterol is a long-acting beta 2 agonist that is administered once daily and authorized for patients with chronic obstructive pulmonary disease (COPD).
  • It has not been clinically proven that this agent is more effective than tiotropium or the other long-acting beta 2 agonists, salmeterol or formeterol.
  • Clinical trials available are short lasting, less than a year, with few patients and important exclusion criteria. Thus, the safety profile of the agent is not conclusive.
  • The rapid onset of its action could result in inadequate use of the drug as rescue therapy.
Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)






Government of Navarre

Contact us | Accessibility | Legal notice | Site map